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Abstract
Bacteriophage or phage therapy involves using phages or their products as 
bio-agents for the treatment or prophylaxis of bacterial infections or diseases. 
Bacteriophages have the ability to regulate the oral microflora by lysing sensitive 
bacterial cells and releasing bacterial components with pro-inflammatory activ-
ity. Bacteriophages carry specific polysaccharide depolymerases that aid viral 
penetration and can disrupt the pathogenic process associated with biofilm and 
exopolysaccharide in the oral cavity. Oral diseases are mainly caused by biofilm 
forming microorganisms and phages are now being used for biocontrol of oral 
biofilms. Phages for Actinomyces species, Aggregatibacter actinomycetemcomitans, 
Enterococcus faecalis, Fusobacterium nucleatum, Lactobacillus species, Neisseria 
species, Streptococcus species, and Veillonella species have been isolated and char-
acterized. Bacteriophages could be considered as potential therapeutic tools for the 
elimination of caries, periodontitis, and other diseases of the oral cavity.
Keywords: oral microbiome, oral phages, oral biofilms, oral diseases, 
bacteriophage therapy
1. Introduction
Bacteriophages are viruses that attack bacteria. Phages are now known to cure 
antibiotic-resistant bacterial infections as well as decrease bacterial virulence by 
overcoming the barriers bacteria used to avoid them. Bacteriophages are now being 
explored as potential therapeutic tools for the elimination of oral bacterial patho-
gens. Bacteriophages can disrupt pathogenic processes associated with biofilm and 
exopolysaccharide formation by oral microflora. Bacteriophages are a habitat to the 
human oral cavity where the oral pathogenic bacteria exist. Earlier studies show 
the isolation of oral bacteriophage from the oral cavity when an oral bacteriophage 
infecting Lactobacillus casei was obtained by Meyer et al. [1]. Subsequently, a range 
of oral bacteriophages infecting Veillonella species was isolated by Hiroki et al. in 
1976, lytic bacteriophages for Actinomyces species were isolated by Tylenda et al. 
in 1985, oral bacteriophages specific for Actinobacillus actinomycetocomitans were 
described by Olsen et al. in 1993, oral bacteriophages specific for Streptococcus 
mutans were isolated by Delisle and Rotkwoski in 1993, and bacteriophages specific 
for Enterococcus faecalis were by Bachrach in 2003 [2–6]. Metagenomic analysis 
estimates 108–1010 virus-like particles existing per ml of human saliva and per gram 
of dental plaque [7]. The isolation studies for oral phages have been challenging, 
where phages have been obtained from clinical (saliva, plaque, oral washings) 
and environmental samples. The bacteriophages for oral bacteria implicated in 
various oral diseases have been described in the following section. The phages 
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for the oral bacteria Actinomyces, Aggregatibacter, Fusobacterium, Parvimonas, 
Porphyromonas, Prevotella intermedia, E. faecalis, S. mutans, Treponema denticola 
are described here.
2. Actinomyces bacteriophages
Actinomyces species are found in healthy mouth but are also implicated in oral 
abcesses and oral-facial actinomycosis. Actinomyces, together with streptococci, 
initiates the biofilm development and formation of dental plaque [8]. Bacteriophages 
are used to block this co-aggregation to reduce the biofilm development without 
reducing health-related Actinomyces, which is part of the oral microbiome. The 
most commonly studied Actinomyces phage was AV-1, but it had a very narrow host 
range [9]. However, when the phage AV-1 was combined with AV-11, they lysed 
most of the indicator strains used for Actinomyces studies [10]. Actinomyces phages 
probably use surface structures of streptococci as receptors. These phages are from 
the families’ Siphoviridae (61%) and Podaviridae (11%) [11, 12].
3. Aggregatibacter bacteriophages
Aggregatibacter is the causative agent of localized aggressive periodonti-
tis. Aggregatibacter phages are mostly temperate phages and easy to isolate. 
Engineered Aggregatibacter bacteriophages that release biofilm degrading enzymes 
like dispersion B to breakdown biofilm have been used against periodontitis caus-
ing Aggregatibacter actinomycetemcomitans [13]. ϕAa 17 and Aaϕ23 are the most 
extensively studied Aggregatibacter phages [14]. These Aaϕ phages have a relatively 
broad host range. The limitation of these Aggregatibacter phages is that they can 
transfer antibiotic resistance genes, which are acquired macrolide lincosamide 
streptogramin B (MLS) resistance genes such as erm (A), erm (B), erm (C), erm 
(F), and erm (Q ), and induce serotype conversion and release of leukotoxin [15]. 
In a recent study, it has been seen by metagenomics analysis that Aggregatibacter 
phages preferably lysogenize specific phylogenetic lineages not correlating with 
specific clinical conditions. They have either a very narrow host range or a broad 
host range [16]. The clinical conditions/impact in which these phages are used 
remains unknown.
4. Enterococcus bacteriophages
E. faecalis is one of the most frequently isolated species from nosocomial infec-
tions, endocarditis, bacteremia, urinary tract infections, meningitis, systemic 
infections. It has also been reported in periodontitis, which is a biofilm-mediated 
disease, tooth root infections, which are an example of endodontic biofilms, and 
also on implants. E. faecalis bacteriophages isolated belong to myoviridae and 
siphoviridae and are tailed phages. The bacteriophages isolated against E. faecalis 
strain of oral origin include phage IME-EF1 when administered intraperitoneally in 
a murine sepsis model protected the mice from lethal challenge around 60 to 80% 
mice surviving [17]. Another phage φEF 24C protected the BALB/C mouse model 
from the lethal challenge of E. faecalis [18]. Another phage EFDG1 tested on E. 
faecalis biofilms of post-treated root canal infections using an ex vivo two-chamber 
bacterial leakage model of human teeth showed dead bacteria in phage-treated 




three phages ϕEF11, EFDG1, and EFLK1 has been studied by genome sequencing 
[20]. Full-genome sequencing of the EFDG1 genome revealed that it did not contain 
harmful genes and also efficiently prevented E. faecalis infection after root canal 
treatment. The authors concluded that phage therapy using these phages might be 
efficacious to prevent E. faecalis infection after root canal treatment. E. faecalis has 
also been recovered from periodontal pockets in 1–51.8% of chronic periodontitis 
patients [21]. In our recent study, a novel E. faecalis bacteriophage was isolated 
from sewage and was found effective in reducing biofilms formed by drug-resistant 
clinical isolates of E. faecalis from chronic periodontitis patients [22]. Passage of 
phage ϕ EF11 through E. faecalis strains JH2–2 harboring a defective prophage 
produced a new strain with more antimicrobial efficacy [23]. The use of enterococci 
bacteriophages can probably control colonization of teeth surfaces by reducing the 
biofilm in chronic periodontitis. The application of bacteriophages as a strategy to 
conventional antibiotic treatment particularly in the case of biofilm and multidrug-
resistant strains is promising.
5. Streptococcus bacteriophages
The most important species that play a key role in dental plaque formation 
are oral Streptococci. The oral streptococci mainly constitute 12 species includ-
ing Streptococcus salivarius, S. agnisosus, S. mutans, S. constellates, S. cristareus, 
Streptococcus gordonii, S. mitis, Streptococcus oralis, S. parasanguis, Streptococcus 
pneumoniae, S. sanguis, S. sobrinus. The initial colonizers of the tooth are S. sali-
varius, S. sanguis, S. oralis, and S.gordonii; however, S. sobrinus and S. mutans are 
more involved in dental infections [24]. Initial studies reported the isolation of 
lytic bacteriophages from human saliva [25]. The complete genome sequence 
of S. mutans lytic bacteriophage M102 was revealed [26]. In 2008, Van de Ploeg 
reported the complete genome sequence of prophage 15 infecting S. gordonii, which 
was a lysogenic phage [24]. A diverse group of around 50 bacteriophages that infect 
S. mitis, S. mutans, S. oralis, S. salivarius, and S. sobrinus have been identified and 
reported [27]. Unlike the S. mutans phages that are seen as lytic phages, the phages 
for S. mitis have been found as temperate. These temperate phages have the property 
to transfer host DNA into other bacterial strains. Seven phage-related gene clusters 
were detected in the genome of S. mitis B6, SM1, and ϕB6 prophages were isolated 
and sequenced [28]. Virulent pneumophages DP-1 and CP-1 were able to infect 
S. mitis and are also able to infect and replicate in commensal streptococci [29]. As 
S. pneumoniae and S. mitis carry numerous temperate phages in their genomes they 
are closely related and these virulent cross-infecting streptococcal phages and their 
enzymes are being used to biocontrol of oral infections [30].
6. Bacteriophages for oral anaerobes
6.1 Fusobacterium bacteriophages
Fusobacterium nucleatum bacteriophages have been isolated from saliva samples 
[31]. Siphovirus Fnpϕ02 could target three subspecies of F. nucleatum, F. vincentii, 
and F. polymorphum. The second phage Fnpϕ02 was rapidly absorbed on the cell 
surface but slow lysis was observed. In another study, non-infective phages were 
obtained by mitomycin C treatment of F. nucleatum [32]. The full-genome sequence 
and functional characterization of a novel lytic bacteriophage FNu1 against 
F. nucleatum which can break down oral biofilms have been reported recently [33].
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6.2 Porphyromonas, prevotella, and tannerella
Prevotella phages have been detected in vivo [34]. Phages against Porphyromonas 
gingivalis and Tannerella forsythia have not been isolated so far. P. gingivalis that is 
an important anaerobic periodontal pathogen-causing microbial dysbiosis may 
protect itself in the periodontal pockets where many bacteriophages are preset by 
CRISPR-CAS systems providing it adaptive immunity [35]. These CRISPR-CAS 
systems are the only adaptive immune system in bacteria to fight phages/viruses, 
plasmids, transposons, integrative conjugative elements and are also found to 
target undesirable bacteria in the microbiome. On invasion or exposure to foreign 
DNA, the spacer sequences are transcribed into small CRISPR RNAs used by Cas 
proteins to cleave foreign DNA thus acquiring “acquired memory” of this adaptive 
immune system.
6.3 Treponema
A single study has reported the isolation of Treponema phage [36]. Phage ϕtd1 
that belongs to Myoviridae family was harvested from the biofilm culture of  
T. denticola and its genome was detected by polymerase chain reaction.
6.4 Veillonella phages
It is a non-motile gram-negative diplococci. Veillonella is a part of the normal 
flora of the mouth is also associated with oral infections. Around 25 Veillonella 
phages have been isolated from mouth wash specimens. The small plaque-forming 
was found to be active against Veillonella rodentium. The large plaque formers were 
active against clinical Veillonella spp. isolates. Virion morphology was studied only 
for functional phages N2, N11, and N20 [37].
6.5 Lactobacillus
Bacteriophages for the caries associated with 12 strains of Lactobacillus includ-
ing L. casei have been isolated. They have been divided into two groups: PL-1 is a 
lytic phage and temperate phage phi FSW of L. casie ATCC27139 [38].
7. Uses of oral bacteriophages
7.1 Bacteriophages and oral biofilms
The effectiveness of oral bacteriophages has been mainly seen by the reduction 
in the count of viable bacteria in the oral biofilms by using them. However, the 
phages were not able to reduce the amount of extracellular matrix in the biofilms 
[39]. Another factor while using phages is the phage therapy will be partially 
effective if particularly if the biofilm is old. The penetration and effect of phages 
on multispecies oral biofilms has also not been much studied. In a study in two 
species of biofilm constituting of phage-resistant and phage-susceptible bacte-
ria, it was seen that the species composition of the biofilm may modulate phage 
effectiveness [40]. Limited studies show the application of oral phages in vivo 
using animal models. The efficacy of oral phages formulated in thermo-sustained 
release system against E. faecalis has been studied in vivo using a rat model. The 





7.2 Bacteriophages in oral diseases
Bacteriophages are being isolated to bacteria causing oral infections. 
Bacteriophages have been isolated to both aerobic and anaerobic microorganisms 
associated with periodontitis. Bacteriophages also constitute the majority of peri-
odontal viral communities [42]. This variation in bacteriophages in healthy and 
periodontitis patients suggests a potential for more bacteriophage exploration. The 
use of bacteriophages has also been done in root canal treatment but targeted mainly 
against E. faecalis. Bacteriophages have also been explored for their therapeutic role 
in peri-implantitis [43] and also in the healing of oral mucosal infections [44].
7.3 Bacteriophages as antibiotic adjuvants
Phages can be used as adjuvants to antibiotic therapy. Resistance developed in 
phages can be reduced by using a cocktail of phages or phage recombinant lysins. 
Now, genetically engineered phages have also been developed to tackle resistance 
strains [45, 46].
The use of strictly lytic phages that infect only the target bacteria without 
affecting the normal microflora can be used as an alternative to local or systemic 
antibiotic therapy. This phage-based treatment can be designed in each case favor-
ing personalized medicine.
8. Conclusion
The oral diseases caries, periodontal diseases, periapical and endodontic lesions, 
perimplantitis, and oral mucosal infections are microbial in origin. Bacteriophages 
are useful candidates for these biofilm-mediated diseases. As antibiotic resistance 
has become a matter of global concern, the bacteriophages or phage therapy can 
be used particularly to reduce the impact of acute infections. Moreover, antibiotics 
have a limited effect on the biofilm and are not much useful for the treatment of 
oral diseases. However, few bacteriophages are not effective against degrading bio-
films; therefore, enzymatic or engineered phages are being investigated. Phages are 
low in cost, easy to isolate, and efficient against biofilm, and are bacteria specific. 
Phages have a great potential to be used in the prevention, control, and therapeutics 
of oral infections.
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